



Attorney Docket: 310844139
PATENT

#11
3-7-00 phone

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ELIEZER RACHAMANN ET AL.

Serial No.: 09/029,543

Group Art Unit: 1623

Filed: FEBRUARY 26, 1998

Examiner: H. Owens, Jr.

Title: PYRIDINIUM DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Forms PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 CFR §1.98(a)(3) for foreign language documents, Applicant directs the Examiner's attention to the International Search Report filed February 28, 1998 indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed without a Certification under 37 CFR §1.97(e) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action or Notice of Allowance (whichever is earlier), and therefore a check for the fee of \$240.00 under 37 CFR

02/27/2000 RISGAYE 00000064 09029543


240.00 0P

§1.17(p) is attached. Please charge any necessary fee or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 05-1323.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. §1.97(d)(2) and that the petition fee set forth in 37 C.F.R. §1.17(i) in accordance with 37 C.F.R. §1.97(d)(3) should be charged to Deposit Account No. 05-1323 (Docket #).

Respectfully submitted,



Herbert I. Cantor
Registration No. 24,392

EVENSON, McKEOWN, EDWARDS
& LENAHAN, P.L.L.C.
1200 G Street, N.W., Suite 700
Washington, DC 20005
Telephone No.: (202) 628-8800
Facsimile No.: (202) 628-8844
February 28, 2000

HIC:pjm